US › Healthcare

Acumen Pharmaceuticals Inc (ABOS)

US · Healthcare · Biotechnology

$2.57-1.53%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-32.7M

EPS

$-0.45

EPS estimate

$-0.39

EPS came in at -0.45 against a street estimate of -0.39 — a miss of 15.4%.

Key statistics

Market cap

$206.8M

Forward P/E

0.0

P/B

3.59

Book value

$0.79

EPS (TTM)

$-1.65

52-week high

$3.60

52-week low

$1.21

50-day MA

$2.60

200-day MA

$2.46

Beta

0.38

Analyst view

Analysts rate Acumen Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.40.

Shareholding

Insiders

6.79%

Institutions

66.59%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	29.03%
Sands Capital Ventures, LLC	5.14%
Alyeska Investment Group, L.P.	3.39%
Franklin Templeton Inc	3.19%
ADAR1 Capital Management LLC	2.98%
Knollwood Investment Advisory LLC	2.25%
Vanguard Capital Management, LLC	2.08%
FMR Inc	1.60%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Acumen Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.